OSCR · Oscar Health, Inc. · Stock research

Current Thesis

The range extended by one more session and gave a little back. The adjusted daily series closed 2026-08-24 at $31.81, against $32.04 on 2026-08-21 and the 2026-08-14 closing high of $32.76 — six consecutive closes without a new high, 2.9% under it. RSI(14) reads 54.9, effectively unchanged from 54.5 on 2026-08-21 and well below 63.9 on 2026-08-14. Over three months the shares are up 45.3%.

Nothing has come from the company since the 2026-08-06 Q2 release, and no new insider record has posted since the 2026-08-20 pair (CFO Form 4, Boyd Form 144). Two observables did move. StockAnalysis's OSCR statistics page, updated 2026-08-25, shows 17.83M shares short — 6.77% of a 263.12M float, 5.78% of 308.33M shares outstanding, 3.79 days to cover — against 18.74M the prior month, so the short base contracted while price went sideways under the high. The same site's forecast page still carries 11 analysts at Hold with a $30.40 mean and $28.50 median target, leaving the last close 4.6% above the mean and 11.6% above the median, with no dated revision since Goldman Sachs moved $22→$30 on 2026-08-17.

The narrative leg an investor is buying: an ACA-exchange insurer that converted a 46% membership gain into two straight quarters of underwriting margin, re-rated roughly 19.9% above the $26.54 level where the post-print advance began, and now needs the 2026-09-16 Investor Day to produce a 2027 number that pulls estimates up to where the tape already trades.

The narrative is maturing. Coverage is established rather than expanding — 11 publishing analysts, a Hold consensus, and both the mean and median target sitting under the last close as of 2026-08-25. The 2026-08-06 beat-and-raise was sold 11.9% on the day. Every target revision that can be dated followed the move: BofA $13→$25 (2026-08-06), UBS $20→$26 and Baird $19→$27 (2026-08-07), Stephens reiterating $34 (2026-08-07), Wells Fargo $20→$27 (2026-08-13), Goldman Sachs $22→$30 (2026-08-17). That last one is now a week old with no follow-on, and the month-over-month decline in shares short says the consolidation is not being fed by covering.

Bullish and bearish views on Oscar Health, Inc.

The model's bull view on Oscar Health, Inc. (OSCR), in brief: Q2 2026 cleared both lines (2026-08-06): EPS $1.10 against $0.49 consensus; revenue $4,880.2M against $4,751M; earnings from operations $388.6M versus a $230.5M operating loss a year earlier; net income $361.8M. The bear view: The tape trades above where the sell side marks it. Both cases follow in full.

Bull Case

• Q2 2026 cleared both lines (2026-08-06): EPS $1.10 against $0.49 consensus; revenue $4,880.2M against $4,751M; earnings from operations $388.6M versus a $230.5M operating loss a year earlier; net income $361.8M.
• Underwriting margin held a second quarter. Q2 MLR 79.2% versus 91.1% in Q2 2025; H1 MLR 75.0%; H1 net income $1,040.8M on revenue $9,527.4M.
• Three of four guide lines moved up on one release (2026-08-06): FY MLR to 81.5–82.5% from 82.4–83.4%; SG&A ratio to 15.6–16.1% from 15.8–16.3%; earnings from operations to $500–700M from $250–450M against $1,092.7M already booked in H1. Revenue reaffirmed at $18.7–19.0B versus a $18.623B estimate.
• Share is arriving as peers withdraw. 2,963,002 effectuated members at 2026-06-30, +46% year over year, while Molina reported 283,000 marketplace members against 655,000 at end-2025 (Molina Q2, 2026-07-22).
• 2027 pricing is filed high across the market. KFF's 2026-08-03 analysis of 276 insurers in all 50 states and DC shows a 15% median proposed increase, with 63% of filings between 10% and 25%. In the prior cycle an 18% proposed median finalized at 20%.
• The enhanced premium tax credit is outside the model. FY26 guidance assumes no extension of credits that lapsed 2025-12-31; the House passed a three-year extension 230–196 on 2026-01-08.

Bear Case

• The tape trades above where the sell side marks it. $31.81 on 2026-08-24 versus a $30.40 mean and $28.50 median target as of 2026-08-25; only Barclays at $39 and Stephens at $34 sit materially above spot.
• The advance has no company disclosure behind it. No dated release since 2026-08-06; the move from $26.54 to $32.76 ran on flow and revisions that trailed price.
• Falling short interest removes squeeze mechanics. 17.83M shares short versus 18.74M the prior month, 3.79 days to cover — a small, shrinking base at 6.77% of float.
• H2 membership churn was flagged by management. The 2026-08-06 call framed accelerating CMS-driven churn as a timing effect; the base already fell from 3.17M at March 31 to 2,963,002 at June 30.
• Single-segment concentration. No Medicaid or Medicare Advantage book to offset a weak marketplace quarter, against a five-year beta of 2.38.

Setup & Price Structure

• Ceiling: the 2026-08-14 close of $32.76. Six closes through 2026-08-24 have failed to take it.
• Last reference close: $31.81 (2026-08-24), 2.9% below that high and 0.7% below the 2026-08-21 close of $32.04.
• First structural shelf: $30.11, the 2026-08-05 print-eve close, 5.3% under the last close. A weekly close beneath it puts price back inside the 2026-08-06 gap-down.
• Second shelf: $26.54, where the post-print advance began, 19.9% under the last close.
• Momentum: RSI(14) 54.9 — mid-range, no extreme in either direction, and a step down from 63.9 on 2026-08-14.
• Crowding observables (state, not verdict): institutional ownership of 239,844,851 shares, 87.81% of shares outstanding across 655 owners, per the 13F cycle closing 2026-08-14, where D. E. Shaw added ~12.6M shares (+130.5%) and Citadel ~4.2M (+22.02%) while Point72 cut 74.31%; short interest 6.77% of a 263.12M float and falling month over month; dated insider supply through 2026-08-18 plus an unresolved 288,514-share notice; beta 2.38.
• No print inside the window. Q3 results are not expected until early November, so the Investor Day is the only scheduled event in the next 30 days that can move estimates rather than move targets up to price.

Catalyst Calendar (next 30 days)

• ~2026-08-31 — State regulators finalize 2027 ACA rates against the 15% median proposed in KFF's 2026-08-03 analysis of 276 filers.
• ~2026-09-10 (est.) — FINRA short-interest report for the 2026-08-31 settlement date; second reading on whether the base keeps shrinking.
• 2026-09-16 — 2026 Investor Day, 9:00 AM ET, webcast on ir.hioscar.com (announced 2026-07-28). Corporate strategy and long-term financial targets.
• ~2026-09-23 (est.) — FINRA short-interest report for the 2026-09-15 settlement date; first reading spanning the Investor Day.
• Just outside the window, ~2026-09-30 — federal appropriations deadline, the nearest plausible vehicle for an enhanced premium tax credit extension.

What Would Change Our Mind

The structure that matters is the 2026-08-05 print-eve shelf at $30.11: losing it on a weekly close below $30.11 returns price inside the 2026-08-06 gap-down and removes the only price evidence that the post-print re-rating was more than a mechanical unwind. Beneath that, a weekly close below $26.54 retraces the entire reaction.

On fundamentals, three observables would break the frame: the 2026-09-16 Investor Day passing with long-term margin targets but no 2027 membership range or premium framework, leaving no scheduled estimate driver until early November; Q3 effectuated membership printing materially below 2,963,002; or FY MLR guidance moving outside the 81.5–82.5% band set on 2026-08-06.

In the other direction, a 2027 membership and premium framework on 2026-09-16 followed by target revisions above the $34 Stephens level, or an enacted enhanced-credit extension, would put a dated estimate change behind a price that currently sits above the $30.40 consensus mean.

Correlation Notes

• Beta 2.38 over five years on a single-segment insurer: managed-care sector drawdowns transmit with no offsetting Medicaid or Medicare Advantage book.
• Peer read-across runs through CNC, MOH and ELV, but inversely on marketplace share — Molina's retreat from 655,000 to 283,000 marketplace members (Q2, 2026-07-22) is share available to survivors and shrinking industry capacity at the same time.
• Premium revenue is overwhelmingly federally subsidized exchange business, so Congressional premium-tax-credit headlines move the stock independent of operating results; the enhanced credits lapsed 2025-12-31 and FY26 guidance assumes no replacement.
• With 87.81% institutional ownership and 6.77% of float short, index and sector flows dominate the marginal bid; the shrinking short base leaves little mechanical demand under the price.